> Products > Product Catalog > Pressure Injectable Maximal Barrier Precautions Tray > Help Prevent Infection

ARROWg+ard® ANTIMICROBIAL TECHNOLOGY

Plug Box

ARROWg+ard is a patented combination of silver sulfadiazine and chlorhexidine impregnated into the catheter surface.

ARROWg+ard is a CDC1B recommendation for the prevention of catheter-related infection, and its ability to help prevent infection, save lives and reduce costs has been supported by more than 30 studies.1,2 No other company’s catheter has such a strong track record, or broad-spectrum activity.

  • Maki et al. found ARROWg+ard reduces bacterial colonization of the catheter by 60 percent and catheter-related bacteremia by an even greater 80 percent.3
  • ARROWg+ard is effective against a wide array of gram-positive bacteria, including S. epidermidis, MRSA and S. aureus; gram-negative bacteria, including Enterococci and Pseudomonas strains; and fungi, including C. albicans.2

Proven protection, inside and out

ARROWg+ard Blue PLUS® catheters are protected both inside and out (including extension lines and hubs). Plus, outside surfaces have three times more chlorhexidine than on our original ARROWg+ard catheters. The result: Chlorhexidine and silver sulfadiazine continuously prep the subcutaneous catheter tract and kill organisms in places that you simply can’t reach. ARROWg+ard Blue PLUS are also the only antimicrobial catheters that have catheter hub and extension line protection.4

Mark E. Rupp, MD, et al., has conclusively proved the efficacy of ARROWg+ard Blue PLUS catheters compared with unprotected catheters.5

REFERENCES:

1 O'Grady, N.P., Alexander, M., Dellinger, E.P., Gerberding, J.L., Heard, S.O., Maki, D.G., Masur, H., McCormick, R.D., Mermel, L.A., Pearson, M.L., Raad, I.I., Randolph, A., Weinstein, R.A. “Guidelines for the Prevention of Intravascular Catheter-Related Infections.” Centers for Disease Control, August 9, 2002, Vol. 51, No. RR10, pp. 7–8.

2 References include but are not limited to Maki 1997, Sampath 1995 and Bach 1994.

3 Maki, D.G., Stolz, S.M., Wheeler, S., Mermel, L.A. “Prevention of Central Venous Catheter-Related Bloodstream Infection With an Antiseptic-Impregnated Catheter: A Randomized, Controlled Trial.” Annals of Internal Medicine, August 15, 1997, Vol. 127, Issue 4, pp. 257–266.

4 Spangler, D., Moss, S. “In Vitro Assessment of Antimicrobial Activity of Three Commercially Available Central Venous Catheters.” Department of Applied Research, Arrow International, Inc., 2007.

5 Rupp, M.E., Lisco, S.J., Lipsett, P.A., Perl, T.M., Keating, K., Civetta, J.M., Mermel, L.A., Lee, D., Dellinger, P.E., Donahue, M., Giles, D., Pfaller, M.A., Maki, D.G., Sherertz, R. “Effect of a Second-Generation Venous Catheter Impregnated With Chlorhexidine and Silver Sulfadiazine on Central Catheter-Related Infections: A Randomized, Controlled Trial.” Annals of Internal Medicine, Vol. 143, No. 8, October 18, 2005, pp. 570–581.

PATENTS: ARROWg+ard® / ARROWg+ard Blue PLUS®: U.S. Patent Nos. 6,706,024 and 6,872,195

Tray1Tray2